Clinical Trials
7 trialsNCT04501120 2026-04-29
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT05147467 2026-03-27
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT06389292 2025-11-25
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT04496349 2025-11-04
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT04494503 2025-04-16
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting
NCT05701306 2025-02-25
APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT03537482 2024-08-19
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
Phase EARLY_PHASE1 Recruiting